ProQR CEO reports stock option holdings
ProQR Therapeutics N.V.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer has filed an initial ownership report listing a series of share options over Ordinary Shares. These options carry exercise prices between $0.66 and $15.78 per share, with expirations from 2026 through 2035. The filing shows existing option holdings only, with no open-market purchases or sales reported.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
de Boer Daniel Anton
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
Holdings:
Share Option (Right to Buy) — 6,740,669 contracts (Direct)
Footnotes (7)
- F1. Fully vested.
- F2. 25% of the shares subject to such option vest and become exercisable on June 1, 2023, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F3. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F4. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F5. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F6. 25% of the shares subject to such option vest and become exercisable on September 23, 2026, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F7. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does ProQR (PRQR) CEO Daniel de Boer report in this Form 3?
Daniel de Boer reports his existing holdings of share options over ProQR Ordinary Shares. The filing lists multiple option grants with different exercise prices and expiration dates, providing a baseline view of his derivative ownership position as a company insider.
Does the ProQR (PRQR) Form 3 show any insider buying or selling?
No, the Form 3 does not show any insider buying or selling. It only discloses existing option positions, with transaction summaries indicating zero purchases, zero sales, and no exercises, gifts, or tax-withholding related dispositions.
What types of securities are disclosed for ProQR (PRQR) CEO in this filing?
The filing discloses “Share Option (Right to Buy)” derivative securities linked to ProQR Ordinary Shares. Each entry shows the exercise price, expiration date, and the number of underlying shares covered by the option, all held directly by Daniel de Boer.
Over what period do Daniel de Boer’s ProQR (PRQR) options expire?
The options disclosed in the filing have expiration dates ranging from the end of 2026 through the end of 2035. This schedule indicates a long-dated option portfolio that extends across multiple years of potential future exercisability.
Do the ProQR (PRQR) CEO’s options have vesting conditions?
Yes, footnotes describe vesting conditions for several option grants. Typically, 25% of the shares vest on a specified initial date, with the remaining 75% vesting in 12 substantially equal quarterly installments, contingent on continuous service with ProQR.
How are the ProQR (PRQR) CEO’s options structured in terms of exercise price?
The options span a range of exercise prices, from $0.66 per share up to $15.78 per share. Each grant’s exercise price is fixed in the filing, defining the cost per share if Daniel de Boer chooses to exercise those options in the future.
AI-generated analysis. How Rhea-AI works. Not financial advice.
